An Interest In:
Web News this Week
- April 23, 2024
- April 22, 2024
- April 21, 2024
- April 20, 2024
- April 19, 2024
- April 18, 2024
- April 17, 2024
Some of Our Sources
- Joshua Blankenship
- Abduzeedo
- TutsPlus - Design
- Web Designer Depot
- Crazy Leaf Design
- Web Design Ledger
- Wal You
- Spyre Studios
- Willems Lab
- Dev To
Help Webnuz
Referal links:
November 28, 2013 02:27 am GMT
After releasing a brief statement when the FDA's decision to block the sale of 23andMe's home DNA testing kits was made public, the company's CEO Anne Wojcicki has sent a letter to her customers further explaining their position relative to the ban and the government agency that oversees and regulates medical devices and technologies. In the letter, sent out to 23andMe registered customers earlier today, Wojcicki begins by reassuring folks that their tech is both solid and trustworthy, and the product of years of development. Accuracy is the central point of the explainer, and she says they remain comfortable with their track record in that regard. This is likely an indirect response to some criticism that surfaced after the letter was made public, suggesting that 23andMe's test may not be nuanced enough to deliver a full picture associated with risks of contracting certain diseases, including breast cancer. Wojcicki characterizes the issue with the FDA as part of an ongoing process to clarify how their service is classified, which explores “new territory” for both parties. It's true that the FDA has never before had to regulate a test that provides general genetic testing beyond just a specific type of disorder. The FDA, for its part, has given 23andMe 15 days to respond to its letter and describe a plan for resolving its issues with the service. You can see the full text of Wojcicki's letter pasted below. Clearly, the company is taking the position that it's providing a service which is accurate to the claims that it makes about what it provides, while the FDA seems worried more about what consumers will do with the info they receive. As with any type of diagnostic information, there's a huge amount of agency left in the hands of the person being diagnosed, but the FDA seems intent on making sure that 23andMe's results don't somehow result in a public that's misinformed about the risks they face. Dear 23andMe Customers, I wanted to reach out to you about the FDA letter that was sent to 23andMe last Friday. It is absolutely critical that our consumers get high quality genetic data that they can trust. We have worked extensively with our lab partner to make sure that the results we return are accurate. We stand behind the data that we return to customers – but we recognize that the FDA needs to be convinced of
Original Link: http://feedproxy.google.com/~r/Techcrunch/~3/Lt0Q0IEVM3A/
23andMe CEO Responds To Customers, Calls The FDA An Important Partner
After releasing a brief statement when the FDA's decision to block the sale of 23andMe's home DNA testing kits was made public, the company's CEO Anne Wojcicki has sent a letter to her customers further explaining their position relative to the ban and the government agency that oversees and regulates medical devices and technologies. In the letter, sent out to 23andMe registered customers earlier today, Wojcicki begins by reassuring folks that their tech is both solid and trustworthy, and the product of years of development. Accuracy is the central point of the explainer, and she says they remain comfortable with their track record in that regard. This is likely an indirect response to some criticism that surfaced after the letter was made public, suggesting that 23andMe's test may not be nuanced enough to deliver a full picture associated with risks of contracting certain diseases, including breast cancer. Wojcicki characterizes the issue with the FDA as part of an ongoing process to clarify how their service is classified, which explores “new territory” for both parties. It's true that the FDA has never before had to regulate a test that provides general genetic testing beyond just a specific type of disorder. The FDA, for its part, has given 23andMe 15 days to respond to its letter and describe a plan for resolving its issues with the service. You can see the full text of Wojcicki's letter pasted below. Clearly, the company is taking the position that it's providing a service which is accurate to the claims that it makes about what it provides, while the FDA seems worried more about what consumers will do with the info they receive. As with any type of diagnostic information, there's a huge amount of agency left in the hands of the person being diagnosed, but the FDA seems intent on making sure that 23andMe's results don't somehow result in a public that's misinformed about the risks they face. Dear 23andMe Customers, I wanted to reach out to you about the FDA letter that was sent to 23andMe last Friday. It is absolutely critical that our consumers get high quality genetic data that they can trust. We have worked extensively with our lab partner to make sure that the results we return are accurate. We stand behind the data that we return to customers – but we recognize that the FDA needs to be convinced ofOriginal Link: http://feedproxy.google.com/~r/Techcrunch/~3/Lt0Q0IEVM3A/
Share this article:
Tweet
View Full Article
Techcrunch
TechCrunch is a leading technology blog, dedicated to obsessively profiling startups, reviewing new Internet products, and breaking tech news.More About this Source Visit Techcrunch